Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich Lenggstrasse, 31/PO-Box 1931, 8032, Zürich, Switzerland.
Dr. Willmar Schwabe GmbH & Co. KG, Willmar-Schwabe-Straße 4, 76227, Karlsruhe, Germany.
J Psychiatr Res. 2019 Aug;115:69-74. doi: 10.1016/j.jpsychires.2019.04.013. Epub 2019 Apr 17.
Disturbed sleep is among the most prevalent hyperarousal symptoms in anxiety disorders. Most drugs recommended for anxiety and insomnia have a sedating effect which is related to their beneficial effect on disturbed sleep. Silexan is a proprietary essential oil from Lavandula angustifolia. This drug has significant anxiolytic and sleep improving properties. Interestingly, these effects are not associated with sedation. Here we asked whether the positive effects on sleep are due to primary pharmacodynamic or secondary, disease related effects. We used the data from a double-blind, randomized study in which 212 patients were analyzed for efficacy after ten weeks' treatment with 80 mg/day Silexan or placebo. Anxiety and disturbed sleep were assessed using the Hamilton Anxiety Scale (HAMA) and the Pittsburgh Sleep Quality Index (PSQI), respectively. Regression-based mediation analysis was employed to estimate direct treatment effects and indirect effects mediated by anxiety control separately for each study group. Sobel's test was used to investigate the extent to which the mediator (HAMA change) contributes to the total effect of the independent variable (treatment) on the dependent variable (PSQI change). Compared to placebo, Silexan significantly reduced the total scores of the HAMA (p < 0.001) and of the PSQI (p = 0.002) after ten weeks, with clinically meaningful treatment group differences that were observed already after two and six weeks for HAMA and PSQI, respectively. Silexan had a statistically meaningful indirect effect on sleep (mediated by the effect on anxiety; p < 0.001) but no appreciable direct effect (p = 0.958). The ratio between the indirect and the total effect was determined to be 0.984, i. e., 98.4% of the total effect of Silexan on disturbed sleep were explained by the effect of Silexan on the symptoms of anxiety whereas 1.6% were attributable to a direct effect. The results indicate that Silexan exerts a secondary sleep improving effect almost exclusively through its anxiolytic action rather than by sedation. Findings are consistent with the drug's assumed mechanism of action.
睡眠障碍是焦虑障碍中最常见的过度觉醒症状之一。大多数推荐用于焦虑和失眠的药物都具有镇静作用,这与其对睡眠障碍的有益作用有关。Silexan 是一种来自狭叶薰衣草的专利精油。这种药物具有显著的抗焦虑和改善睡眠的特性。有趣的是,这些作用与镇静无关。在这里,我们想知道改善睡眠的积极作用是否是由于药物的主要药效学作用还是次要的、与疾病相关的作用。我们使用了一项双盲、随机研究的数据,该研究对 212 名患者进行了分析,这些患者在接受 80mg/天 Silexan 或安慰剂治疗 10 周后的疗效。焦虑和睡眠障碍分别采用汉密尔顿焦虑量表(HAMA)和匹兹堡睡眠质量指数(PSQI)进行评估。采用基于回归的中介分析分别估计每个研究组中焦虑控制的直接治疗效果和间接效果。Sobel 检验用于调查中介变量(HAMA 变化)对自变量(治疗)对因变量(PSQI 变化)的总效应的贡献程度。与安慰剂相比,Silexan 在 10 周后显著降低了 HAMA 的总分(p<0.001)和 PSQI 的总分(p=0.002),在 HAMA 和 PSQI 方面,治疗组之间的差异在 2 周和 6 周后就具有临床意义。Silexan 对睡眠具有统计学上的显著间接影响(通过对焦虑的影响介导;p<0.001),但没有明显的直接影响(p=0.958)。间接效应与总效应的比值为 0.984,即 Silexan 对睡眠障碍的总效应的 98.4%是通过 Silexan 对焦虑症状的影响来解释的,而 1.6%归因于直接效应。结果表明,Silexan 通过其抗焦虑作用发挥次要的改善睡眠作用,而不是通过镇静作用。这些发现与药物的假定作用机制一致。